双相与单相抑郁的代谢组学生物标志物特征
该诊断分析基于Delta研究(英国,2018-2020年),在近期诊断MDD且当前有抑郁症状的患者中,用干血斑靶向质谱检测代谢物并结合患者自报信息,识别出17种生物标志物组合可区分BD与MDD,交叉验证AUROC为0.71(SD 0.12,P < .001)。
要点
- 17种干血斑代谢物组合区分BD与MDD的交叉验证AUROC为0.71(SD 0.12,P < .001)。
- 神经酰胺d18:0/24:1为最强单个生物标志物。
- 生物标志物与患者自报信息结合可显著提升诊断模型性能。
核心结论
- 该研究为开发可及性生物标志物检测以辅助BD与MDD的鉴别诊断提供了概念验证,并提示神经酰胺可能参与心境障碍的病理生理机制。
研究设计与样本
- 诊断分析使用Delta研究(英国,2018年4月27日至2020年2月6日)的样本与数据,分析于2022年2月至2023年7月进行。
- 发现队列241例近期诊断MDD且当前抑郁症状(PHQ-9≥5)的患者,其中67例(27.8%)随后诊断为BD、174例(72.2%)确诊MDD;平均(SD)年龄28.1(7.1)岁,170例(70.5%)女性。
- 验证队列30例,其中9例(30%)诊断为BD、21例(70%)为MDD;平均(SD)年龄25.4(6.3)岁,16例(53%)女性。
- 通过在线问卷收集患者数据(n=635问题),用靶向质谱平台分析干血斑代谢物(n=630),心境障碍诊断采用复合国际诊断访谈(CIDI)。
主要发现
- 17种生物标志物组合的交叉验证AUROC平均(SD)为0.71(0.12;P < .001),神经酰胺d18:0/24:1为最强生物标志物。
- 生物标志物数据与患者自报信息结合,显著提升了基于广泛人口学数据、PHQ-9评分及心境障碍问卷(MDQ)结果的模型诊断性能。
- 所识别生物标志物主要与终生躁狂症状相关。
- 在1年随访期间新临床诊断为MDD(n=21)或BD(n=9)的独立患者组中验证,平均(SD)AUROC为0.73(0.06;P < .001)。
关键数值与推荐
- 发现队列中BD与MDD的区分采用17种干血斑代谢物组合,交叉验证AUROC为0.71(SD 0.12;P < .001)。
- 验证队列中该生物标志物组合的AUROC为0.73(SD 0.06;P < .001)。
临床怎么用
- 在近期诊断MDD且当前有抑郁症状的患者中,可考虑干血斑代谢组学检测辅助BD与MDD的鉴别诊断。
- 将生物标志物结果与患者自报信息(如PHQ-9、MDQ及人口学数据)结合,可能提升鉴别诊断模型性能。
局限性
- 研究为概念验证性诊断分析,发现队列241例、验证队列30例,样本量有限。
- 参与者通过在线自愿响应抽样招募,可能存在选择偏倚。
- 生物标志物组合的交叉验证AUROC为0.71,区分性能中等,仍需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bipolar disorder (BD) is frequently misdiagnosed as major depressive disorder (MDD) because of overlapping symptoms and the lack of objective diagnostic tools. OBJECTIVE: To identify a reproducible metabolomic biomarker signature in patient dried blood spots (DBSs) that differentiates BD from MDD during depressive episodes and assess its added value when combined with self-reported patient information. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic analysis used samples and data from the Delta study, conducted in the UK between April 27, 2018, and February 6, 2020. The primary objective was to identify BD in patients with a recent (within the past 5 years) diagnosis of MDD and current depressive symptoms (Patient Health Questionnaire-9 score of 5 or more). Participants were recruited online through voluntary response sampling. The analysis was carried out between February 2022 and July 2023. MAIN OUTCOMES AND MEASURES: Patient data were collected using a purpose-built online questionnaire (n = 635 questions). DBS metabolites (n = 630) were analyzed using a targeted mass spectrometry-based platform. Mood disorder diagnoses were established using the Composite International Diagnostic Interview. RESULTS: Of 241 patients in the discovery cohort, 170 (70.5%) were female; 67 (27.8%) were subsequently diagnosed with BD and 174 (72.2%) were confirmed as having MDD; and the mean (SD) age was 28.1 (7.1) years. Of 30 participants in the validation cohort, 16 (53%) were female; 9 (30%) were diagnosed with BD and 21 (70%) with MDD; and the mean (SD) age was 25.4 (6.3) years. DBS metabolite levels were assessed in 241 patients with depressive symptoms with a recent diagnosis of MDD, of whom 67 were subsequently diagnosed with BD by the Composite International Diagnostic Interview and 174 were confirmed as having MDD. The identified 17-biomarker panel provided a mean (SD) cross-validated area under the receiver operating characteristic curve (AUROC) of 0.71 (SD, 0.12; P < .001), with ceramide d18:0/24:1 emerging as the strongest biomarker. Combining biomarker data with patient-reported information significantly enhanced diagnostic performance of models based on extensive demographic data, PHQ-9 scores, and the outcomes from the Mood Disorder Questionnaire. The identified biomarkers were correlated primarily with lifetime manic symptoms and were validated in a separate group of patients who received a new clinical diagnosis of MDD (n = 21) or BD (n = 9) during the study's 1-year follow-up period, with a mean (SD) AUROC of 0.73 (0.06; P < .001). CONCLUSIONS AND RELEVANCE: This study provides a proof of concept for developing an accessible biomarker test to facilitate the differential diagnosis of BD and MDD and highlights the potential involvement of ceramides in the pathophysiological mechanisms of mood disorders.
引用
- Tomasik J, Harrison SJ, Rustogi N, et al. Metabolomic Biomarker Signatures for Bipolar and Unipolar Depression. JAMA Psychiatry. 2024. PMID: 37878349. doi:10.1001/jamapsychiatry.2023.4096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。